Aileron Therapeutics, Inc. (ALRN) News
Filter ALRN News Items
ALRN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALRN News Highlights
- For ALRN, its 30 day story count is now at 2.
- Over the past 20 days, the trend for ALRN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ALRN are DRUG.
Latest ALRN News From Around the Web
Below are the latest news stories about AILERON THERAPEUTICS INC that investors may wish to consider to help them evaluate ALRN as an investment opportunity.
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowAileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
Cancer drugmaker down to 3 employees after trial failureA cancer firm has gone from a paltry nine employees to an even scanter three after a chemoprotective drug failed in clinical trials. |
Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares FallAileron Therapeutics (NASDAQ: ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast cancer showed severe neutropenia (Grade 4) and alopecia (hair loss). The primary endpoint of the Phase 1b open-label trial was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or "TAC" chemotherapy, was the duration and incidence of severe neutropenia |
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic AlternativesBOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint of the Phase 1b open-label trial, which was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, a |
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy StockAileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Aileron Therapeutics Regains Compliance with Nasdaq Listing RequirementsBOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 p |
Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAileron Therapeutics, Inc. (ALRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
Aileron Therapeutics Announces a 1-for-20 Reverse Stock SplitCommon Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. ET today. Aileron’s common stock will continue to be traded on the |
Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the UpgradeAileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
JonesTrading Reaffirms Their Hold Rating on Aileron Therapeutics (ALRN)In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on Aileron Therapeutics (ALRN - Research Report). The company's shares opened today at $0.21.Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and AVEO Pharma. According to TipRanks, Roy has an average return of 6.7% and a 32.49% success rate on recommended stocks. The analyst consensus on Aileron Therapeutics is currently a Hold rating.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $0.94 and a one-year low of $0.13. Currently, Aileron Therapeutics has an average volume of 1.14M. |